Stockscreener 앱 받기
1,038.40
0.53%
5.43
전일 마감가:
$1,032.97
열려 있는:
$1024.43
하루 거래량:
3.84M
Relative Volume:
1.11
시가총액:
$929.39B
수익:
$59.42B
순이익/손실:
$18.41B
주가수익비율:
51.36
EPS:
20.2197
순현금흐름:
$6.44B
1주 성능:
-2.37%
1개월 성능:
-1.51%
6개월 성능:
+31.48%
1년 성능:
+37.06%
1일 변동 폭
$1,018.00
$1,049.94
1주일 범위
$1,012.57
$1,090.22
52주 변동 폭
$623.78
$1,133.95
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,038.40 | 924.53B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.66 | 529.01B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.35 | 383.08B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVO
Novo Nordisk Adr
|
62.33 | 253.81B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
NVS
Novartis Ag Adr
|
144.34 | 274.68B | 54.45B | 14.42B | 17.15B | 7.333 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-16 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 재확인 | BofA Securities | Buy |
| 2025-12-15 | 재확인 | Goldman | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026? - The Motley Fool
Eli Lilly Shares Face Pressure Following Regulatory Setback - AD HOC NEWS
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week - TechStock²
This pharmaceutical executive has Trump's ear - Politico
BMO Reaffirms Eli Lilly and Company (LLY) as an Obesity Market Leader - Finviz
Eli Lilly’s Strategic Moves in the Weight-Loss Drug Arena - AD HOC NEWS
Eli Lilly Partners with Nvidia to Invest $1 Billion in AI Drug Discovery - Intellectia AI
Eli Lilly: A Strong Player in the Pharmaceutical Arena - The Motley Fool
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang - TechStock²
Chai Discovery and Eli Lilly Partner to Accelerate AI-Driven Drug Development - Букви
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development - TechCrunch
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - The Motley Fool
Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly - Reuters
Continuous Bioprocessing Market Set to Surpass Valuation of US$ 2,331.98 Million By 2035 | Astute Analytica - GlobeNewswire Inc.
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Yahoo Finance Singapore
Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know. - The Motley Fool
NVIDIA and Lilly launch $1B AI lab for drug discovery ... - eeNews Europe
Rakuten Securities Inc. Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Has $15.61 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
NVIDIA and Eli Lilly Launch AI Co-Innovation Lab for Drug Development - HLTH
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed - TechStock²
Forbes J M & Co. LLP Acquires 3,186 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Holdings Reduced by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Blalock Williams LLC Buys New Position in Eli Lilly and Company $LLY - MarketBeat
[JPM 2026] ABL Bio seeks next license-out after GSK, Eli Lilly deals - theinvestor.co.kr
Regulatory Hurdles and Legal Challenge Weigh on Eli Lilly Shares - AD HOC NEWS
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10 - TechStock²
Lobbying Update: $2,200,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
IU and Eli Lilly team up to study impact of GLP-1 drugs in workplace - WRTV
Eli Lilly and Novo Nordisk Accused of Blocking Access to Lower-Cost Weight-Loss Drugs - PYMNTS.com
Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers - Benzinga
Why Eli Lilly (LLY) Stock Is Down Today - Finviz
Eli Lilly (LLY) Faces Potential Delay in Weight Loss Pill Approval - GuruFocus
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Stocktwits
Eli Lilly drops as FDA decision on weight loss pill is now expected in April - Seeking Alpha
JPM: NVIDIA and Eli Lilly announce co-innovation AI lab - MobiHealthNews
Where is Eli Lilly and Company (LLY) Headed According to Analysts? - Insider Monkey
Nvidia and Lilly to create AI co-innovation lab - The Pharma Letter
Eli Lilly Stock (LLY) Falls 5% After FDA Delays Decision on Weight-Loss Pill - TipRanks
Eli Lilly and Co (LLY) Shares Down 4.92% on Jan 15 - GuruFocus
Eli Lilly (LLY) Stock Dips Amid FDA Review Delay on Weight-Loss Pill - GuruFocus
Eli Lilly slips in pre-market! New pill still under FDA scrutiny 💊 - XTB.com
AMD, Eli Lilly among market cap stock movers on Thursday - Investing.com
Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy - Reuters
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent - PharmaLive
JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus - Clinical Trials Arena
Eli Lilly and Company Stock (LLY) Opinions on Obesity Drug Partnership and AI Investment - Quiver Quantitative
JPM26: Eli Lilly’s obesity drugs target commercial and governmental access - Pharmaceutical Technology
WealthPLAN Partners LLC Grows Position in Eli Lilly and Company $LLY - MarketBeat
WealthPlan Investment Management LLC Has $1.56 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly shares dip as FDA delays decision on weight-loss pill - Investing.com
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
9.12%
자본화:
|
볼륨(24시간):